title: [Serous otitis media. Comparative study of carbinoxamine- pseudoephedrine vs astemizole-pseudoephedrine].
abstract: They were studied 48 children of 3 to 8 years old, of two sex (30 male and 18 female), that attended the external service of otolaryngology of the Hospital of the ISSSTE of Nuevo Laredo, Tamaulipas (Mexico) and the private practice of the Allergy Clinic and Otolaringol in Nuevo Laredo, Tamaulipas, of the month of November of 1995 to April of 1996. Some of the side effects observed in the patients treated in the group A (carbinoxamine-P) were: mild sedation and in some instances hyperexcitability and irritability. However, it was not necessary to discontinue the medication or to modify the dose. In the group B (astemizole-P) was observed only excitement and irritability in some instances by hypersensitivity to the pseudoephedrine. It is very important to consider that the adequate and timely treatment in a patient with otitis serous media will permit to avoid sequels that they can cause, in the long run, a meaningful impact in the language and intellectual development of the child.
authors.affiliation: Pediatra alergóloga, Hospital San José, Nuevo Laredo, Tamps.
authors.forename: N J
authors.initials: NJ
authors.lastname: Pérez Carmona
authors.forename: M A
authors.initials: MA
authors.lastname: García
authors.forename: T
authors.initials: T
authors.lastname: Fuentes Rejón
mesh_terms: D016589:Astemizole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004809:Ephedrine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D008297:Male; D014663:Nasal Decongestants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010034:Otitis Media with Effusion / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012894:Sleep Stages; D016896:Treatment Outcome
chemical_list: D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D011725:Pyridines; D016589:Astemizole; C004649:carbinoxamine; D004809:Ephedrine